Topical Tranexamic Acid After Intravitreal Injections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

NCT04234932

Glaucoma, Open-Angle

UNKNOWN EARLY_PHASE1

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

NCT00370266

Branch Retinal Vein Occlusion

COMPLETED PHASE2

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

NCT00864838

COMPLETED PHASE2

Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm

NCT02120066

Submacular Hemorrhage Ruptured Retinal Arterial Macro Aneurysms

COMPLETED NA

Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema

NCT01299129

Uveitis Related Cystoid Macular Edema

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subconjunctival Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical tranexamic acid

Group Type EXPERIMENTAL

Tranexamic acid

Intervention Type DRUG

A single drop administered topically

Topical BSS

Group Type PLACEBO_COMPARATOR

Balanced Salt Solution

Intervention Type OTHER

A single drop administered topically

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid

A single drop administered topically

Intervention Type DRUG

Balanced Salt Solution

A single drop administered topically

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects receiving intravitreal injections as part of their routine ophthalmological care

Exclusion Criteria

Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes